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Abstract: A series of 4-(substituted)-N-(guanidinyl)benzenesulfonamides bearing biologically 
active pyrazole, pyrimidine and pyridine moieties were prepared and evaluated for their 
anticancer activity against human tumor breast cell line (MCF7). These sulfonamides showed 
promising activity with IC50 values ranging from 49.5 to 70.2 μM. The structure-activity 
relationship of the synthesized compounds was studied. Interestingly, it was found that  
the most potent compounds in this study were the corresponding 2-cyanoacrylate 3,  
3-oxobutanoate 4, pyrazole 6, pyridine 9 and pyrazole 13. Compounds 7 and 8 are nearly as 
active as Doxorubicin as reference drug with (IC50 values = 70.2, 68.1 μM), while compounds 
5, 10 and 11 exhibited a moderate activity.  
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1. Introduction 
Cancer, known medically as malignant neoplasia, is a broad group of diseases involving 
unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, 
which may invade nearby parts of the body. The cancer may also spread to more distant parts of the 
body through the lymphatic system or bloodstream [1,2]. Breast cancer is a kind of cancer that 
develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the 
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lobules that supply them with milk. A malignant tumor can spread to other parts of the body [3,4]. The 
vast majority of breast cancer cases occur in females and breast cancer is the most common invasive 
cancer in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers 
in women. Including both males and females, 18.2% of all cancer deaths worldwide are from breast 
cancer [5,6]. Treatments for breast cancer include surgery as well as radiation, chemotherapy and 
hormonal therapy; these treatments are either local or systemic. Local treatments, such as surgery and 
radiation therapy, remove, destroy or control cancer cells in specific areas. Systemic treatments, such 
as chemotherapy and hormonal therapy, destroy or control cancer throughout the body. Depending on 
the condition, one may receive one treatment or a combination at the same time or in succession [7]. 
Nitrogen heterocycles are of special interest because they constitute an important class of natural 
and non-natural products, many of which exhibit useful biological activities. Pyrazoles and their derivatives 
exhibit a broad spectrum of biological activities such as antimicrobial [8], anti-inflammatory [9], and 
antitumor activities [10]. With growing application on their synthesis and bioactivity, chemists and 
biologists in recent years have directed considerable attention on the research of pyrazole derivatives. 
Pyrimidines are of chemical and pharmacological interest and compounds containing the pyrimidine 
ring system have been shown to possess antimicrobial [11,12], antimalarial [13], anticonvulsant [14], 
and antitumor activities [15]. Some are valuable drugs for the treatment of acute leukemia in children 
and adult granulocytic leukemia [16]. Compounds containing a pyridine moiety as a precursor have 
proven to possess several biologically properties especially as anticancer agents [17–19]. These 
findings led us to enlarge our investigations and to continue working on the synthesis of biologically 
active compounds [20–25] to synthesize a series of 4-(substituted)-N-(guanidinyl)benzenesulfonamides 
in order to evaluate if the presence of the guanidine moiety could enhance their biological activities. 
The choice of guanidine derivatives is due to its presence in several classes of pharmacological active 
compounds, recently anticancer drugs [26,27], and also in some commercially available drugs for 
example, the anti-diabetic metformin which is an oral anti-diabetic drug in the biguanide class  
and the first-line drug of choice for the treatment of type 2 diabetes [28–30]; the anticoagulant 
Nafamostatmesilate [31]; cimetidine which is a histamine H2-receptor antagonist that inhibits stomach 
acid production and largely used in the treatment of heartburn and peptic ulcers [32]. Gabexate is a 
serine protease inhibitor which is used therapeutically (as Gabexatemesilate) in the treatment of 
pancreatitis, and disseminated intravascular coagulation [33] (Figure 1). 
Figure 1. Some commercially available guanidine containing drugs. 
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2. Results and Discussion 
2.1. Chemistry 
In this work, the reactivity of sulfaguanidine1 with active methylenes (malononitril,  
2-(ethoxymethylene)malononitrile, ethylcyanoacetate, (ethoxymethylene)ethylcyanoacetate, 
ethylacetoacetate and acetylacetone) was studied. The reactions proceeded according to the reported 
method [24] and the obtained sulfonamide derivatives 2–5, respectively, were identified by elemental 
and spectral data (Scheme 1). Due to the biological importance of pyrazole, pyridine and pyrimidine 
rings as anticancer agents, the strategic starting materials sulfonamide derivatives 2 and 5 were reacted 
with different nucleophiles in order to obtain biologically active pyrazole, pyridine and pyrimidine 
derivatives bearing sulfonamide moieties. Thus, interaction of sulfonamide derivatives 2 with either 
hydrazine hydrate or methylhydrazine yielded the corresponding pyrazole derivatives 6 and 7, the 
formation of the pyrazole ring was proved by the disappearance of CN in the infrared spectra and the 
appearance of NH2 bands which is also traced in their 
1H-NMR spectra and were exchangeable with 
D2O, 
1H-NMR spectrum of compound 7 showed a singlet at 2.4 ppm corresponding to the methyl 
group, while, their 13C-NMR spectra showed the appearance of signals for the carbons of the pyrazole 
rind at 166.4 ppm for compound 6 and 163.8 ppm for compound 7. On the other hand, interaction of 
compound 2 with chloroacetyl chloride in dioxane as a solvent containing triethylamine as catalyst 
yielded the corresponding pyridine derivatives 9 which was characterized by the presence of CN band 
and appearance of new bands for NH2, carbonyl and C-Clgroups in the infrared spectrum and the 
specific signals of the pyridine ring appeared in the 13C-NMR spectrum. Reaction of compound 2 with 
phenyl isothiocyanate in NaOH/ethanol and/or thiourea gave the corresponding pyrimidine-2-thione 
derivatives 8 or 10, respectively and their structure were proved by microanalytical and spectral data 
(Scheme 2). Similarily, the sulfonamide derivative 5 was reacted with either hydrazine hydrate, 
methylhydrazine or phenylhydrazine yielded the corresponding pyrazole derivatives 11–13, respectively. 
On the other hand, interaction of compound 5 with thiourea and/or phenyl isothiocyanate in NaOH/ethanol 
gave the corresponding pyrimidine and pyridine derivatives 14 and 15, respectively (Scheme 3). 
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2.2. In-Vitro Anticancer Screening 
Doxorubicin, the reference drug used in this study is a drug used in cancer chemotherapy. It is an 
anthracycline antibiotic, it works by intercalating DNA and inhibition of macromolecular biosynthesis. 
This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for 
transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain 
for replication, preventing the DNA double helix from being resealed and thereby stopping the process 
of replication. It is commonly used in the treatment of a wide range of cancers as in acute leukemia’s 
Hodgkin’s disease, and other lymphomas and cancers of the breast, adrenal cortex, endometrium, lung, 
ovary, and other sites [34]. The relationship between surviving fraction and drug concentration was 
plotted; the response parameters calculated was IC50 value, which corresponds to the compound 
concentration that causes 50% inhibition of cellular viability (Table 1). From Table 1, we can observe 
that all the tested compounds were found to be equipotent or even more potent than Doxorubicin on 
the MCF7 cell line with IC50 values ranging from 49.5 to 70.2 µM. The most potent compounds  
in this study are compound 3 bearing 2-cyanoacrylate moiety (IC50 = 49.5 µM), 3-oxobutanoate 
derivative 4 (IC50 = 54.8 µM), pyrazole derivative 6 (IC50 = 59.0 µM), pyridine 9 (IC50 = 59.2 µM) and 
the pyrazole derivative 13 (IC50 = 57.8 µM), and they were found to be more potent than the reference 
drug Doxorubicin (IC50 = 71.8 µM). On the other hand, the pyrazole derivative 7 and pyrimidine 8 
were found to be nearly as potent as the positive control Doxorubicin with IC50 = 70.2, 68.1 µM, 
respectively. In addition compounds 5, 10, and 11 exhibited a moderate activity with IC50 = 75.3, 76.1, 
75.6 µM, respectively. Finally, the least potent are compounds 12 (IC50 = 102.9 µM) and 14, which 
showed no activity on MCF7 cell line. These results attract the attention of the possible use of the 
synthesized pyrazole, pyridine and pyrimidine derivatives carrying a biologically active sulfonamide 
moiety for treatment of breast tumors and these results are in agreement with previous studies done on 
pyrazole, pyridine and pyrimidine and other sulfonamide derivatives and resulted in compounds with 
promising anticancer activities [20–25]. 
Table 1. In-vitro anticancer screening of compounds 3–14 against human breast cell  
line (MCF7). 
Compound No. IC50 (µg/mL) IC50 (µM) 
3 16.7 49.5 
4 19.4 54.8 
5 24.4 75.3 
6 19.0 59.0 
7 23.6 70.2 
8 29.0 68.1 
9 21.7 59.2 
10 23.3 76.1 
11 24.2 75.6 
12 34.4 102.9 
13 22.9 57.8 
14 NA NA 
Doxorubicin 39.0 71.8 
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3. Experimental Section 
3.1. Chemistry 
Reagents were obtained from commercial suppliers and were used without purification. Melting 
points were determined in open capillary tubes using Thermo system FP800 Mettler FP80 central 
processor (Stuart Scientific, Redhill, UK) supplied with FP81 MBC cell apparatus, and were uncorrected. 
Elemental analyses (C, H, N) were performed on a Perkin-Elmer 2400 Instrument (Perkin-Elmer, 
Norwalk, CT, USA). All compounds were within ±0.4% of the theoretical values. Infrared (IR) spectra  
(KBr disc) were recorded on FT-IR spectrophotometer (Perkin Elmer, Norwalk, CT, USA) at the 
Research Center, College of Pharmacy, King Saud University, Saudi Arabia.1H- and 13C-NMR spectra 
were recorded on a Ultra Shield Plus 500 MHz (Bruker, Munich, Germany) spectrometer operating at 
500 MHz for proton and 125 MHz for carbon, respectively. The chemical shift values are reported in δ 
(ppm) relative to the residual solvent peak, the coupling constants (J) are reported in Hertz (Hz).  
3.1.1. N-Carbamimidoyl-4-(2,2-cyanovinylamino)benzenesulfonamide (2) 
A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), malononitrile (0.66 g, 0.01 mol), triethylorthoformate 
(1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction 
mixture was filtered, the filtered solid was crystallized from ethanol to give 2. Yield%: 85, m.p. = 274.6 °C, 
IR, cm−1: 3446, 3338, 3205 (NH, NH2), 3100 (CH arom.), 2930, 2846 (CH aliph.), 2212 (CN),  
1634 (C=N), 1368, 1151 (SO2). 
1H-NMR (DMSO-d6, ppm): 6.1[s, 1H, CH], 6.7[s, 2H, NH2,  
D2O-exchangeable], 7.5, 7.7[2d, 4H, Ar–H, AB system, J = 7.1 Hz], 8.5[s, 1H, NH–imino,  
D2O-exchangeable], 11.3[s, 2H, NH + SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 56.0, 
113.8 (2), 117.7 (2), 126.0 (2), 140.6, 141.2, 155.8, 158.0. Anal. Calcd for C11H10N6O2S (290):  
C, 45.51; H, 3.47; N, 28.95. Found: C, 45.21; H, 3.80; N, 28.62. 
3.1.2. (E)-Ethyl-3-(4-(N-carbamimidoylsulfamoyl)phenylamino)-2-cyanoacrylate (3) 
A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), ethylcyanoacetate (1.13 g, 0.01 mol), 
triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed  
for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 3. 
Yield%: 83, m.p. = 143.6 °C, IR, cm−1: 3433, 3381, 3291 (NH, NH2), 3056 (CH arom.), 2961, 2836  
(CH aliph.), 2220 (CN), 1713 (C=O), 1635 (C=N), 1362, 1168 (SO2). 
1H-NMR (DMSO-d6, ppm): 
1.2[t, 3H, CH3], 4.1[q, 2H, CH2], 5.7[s, 2H, NH2, D2O-exchangeable], 6.5–7.7[m, 5H, Ar–H + CH], 
8.5[s, 1H, NH–imino, D2O-exchangeable], 11.0[s, 2H, NH + SO2NH, D2O-exchangeable]. 
13C-NMR 
(DMSO-d6, ppm): 13.8, 61.9, 76.1, 112.1, 117.6 (2), 127.2 (2), 130.6, 141.8, 151.3, 158.0, 164.2. Anal. 
Calcd for C13H15N5O4S (337): C, 46.28; H, 4.48; N, 20.76. Found: C, 46.51; H, 4.80; N, 20.44. 
3.1.3. (E)-Ethyl-2-((4-(N-carbamimidoylsulfamoyl)phenylamino)methylene)-3-oxobutanoate (4) 
A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), ethylacetoacetate (1.30 g, 0.01 mol), 
triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed  
for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 4. 
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Yield%: 83, m.p. = 173.9 °C, IR, cm−1: 3433, 3390, 3236 (NH, NH2), 3100 (CH arom.), 2919, 2880 
(CH aliph.), 1710, 1699 (2C=O), 1612 (C=N), 1384, 1167 (SO2). 
1H-NMR (DMSO-d6, ppm):  
1.2[t, 3H, CH3], 2.3[s, 3H, COCH3], 4.1[q, 2H, CH2], 5.6[s, 2H, NH2, D2O-exchangeable], 6.5,  
7.4[2d, 4H, Ar–H, AB system, J = 7.3 Hz], 8.4[s, 1H, NH–imino, D2O-exchangeable], 10.2[s, 2H, 
NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 13.9, 24.8, 59.6, 102.7, 118.2 (2), 
126.5 (2), 127.2, 148.8, 151.3, 157.7, 169.1, 194.9. Anal. Calcd for C14H18N4O5S (354): C, 47.45;  
H, 5.12; N, 15.81. Found: C, 47.12; H, 4.80; N, 15.44. 
3.1.4. 4-(2-Acetyl-3-oxobut-1-enylamino)-N-carbamimidoylbenzenesulfonamide (5) 
A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), acetylacetone (1.00 g, 0.01 mol), triethylorthoformate 
(1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction 
mixture was filtered, the filtered solid was crystallized from ethanol to give 5. Yield%: 81, m.p. = 162.0 °C, 
IR, cm−1: 3435, 3339, 3132 (NH, NH2), 3099 (CH arom.), 2961, 2834 (CH aliph.), 1721, 1701 
(2C=O), 1612 (C=N), 1384, 1156 (SO2). 
1H-NMR (DMSO-d6, ppm): 2.4[s, 6H, 2COCH3],  
6.6[s, 2H, NH2, D2O-exchangeable], 7.3, 7.7[2d, 4H, Ar–H, AB system, J = 7.0 Hz], 7.9[s, 1H, CH], 
8.8[s, 1H, NH–imino, D2O-exchangeable], 12.5[s, 2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR 
(DMSO-d6, ppm): 23.0 (2), 112.3, 118.1 (2), 127.1 (2), 129.4, 140.2, 142.2, 158.9, 196.1 (2). Anal. 
Calcd for C13H16N4O4S (324): C, 48.14; H, 4.97; N, 17.27. Found: C, 48.34; H, 4.80; N, 17.47. 
3.1.5. N-Carbamimidoyl-4-((3,5-diamino-4H-pyrazol-4-ylidene)methylamino)benzensulfonamide (6) 
A mixture of 2 (2.90 g, 0.01 mol) and hydrazine hydrate (0.50 g, 0.01 mol) in dioxane (20 mL) was 
refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid product 
was filtered and crystallized from methanol to give compound 6. Yield%: 76, m.p. = 117.6 °C,  
IR, cm−1: 3398, 3340, 3276 (NH, NH2), 3066 (CH arom.), 2961, 2836 (CH aliph.), 1618 (C=N), 1384, 
1179 (SO2). 
1H-NMR (DMSO-d6, ppm): 6.54[s, 2H, NH2, D2O-exchangeable], 6.59[s, 4H, 2NH2-pyrazole, 
D2O-exchangeable], 6.9–7.4[m, 5H, Ar–H + CH], 8.4[s, 1H, NH–imino, D2O-exchangeable],  
9.4[s, 2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 112.3, 115.3 (2), 127.2 (2), 
130.7, 144.0, 151.3, 157.7, 166.4 (2). Anal. Calcd for C11H14N8O2S (322): C, 40.99; H, 4.38; N, 34.76. 
Found: C, 40.76; H, 4.67; N, 34.45. 
3.1.6. 4-((3-Amino-5-imino-1-methyl-1H-pyrazol-4-(5H)-ylidene)methylamino)-N-carbamimidoyl-
benzenesulfonamide (7) 
A mixture of 2 (2.90 g, 0.01 mol) and methylhydrazine (0.46 g, 0.01 mol) in dioxane (20 mL) was 
refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid 
products were filtered and crystallized from methanol to give compound 7. Yield%: 89, m.p. = 129.4 °C, 
IR, cm−1: 3401, 3378, 3312 (NH, NH2), 3026 (CH arom.), 2981, 2860 (CH aliph.), 1595 (C=N), 1368, 
1156 (SO2). 
1H-NMR (DMSO-d6, ppm): 2.4[s, 3H, CH3], 6.54[s, 2H, NH2, D2O-exchangeable],  
6.56[s, 2H, NH2pyrazole, D2O-exchangeable], 7.3–7.5[m, 6H, Ar–H + CH + NH pyrazole], 7.7[s, 1H, 
NH–imino, D2O-exchangeable], 9.3[s, 2H, NH + SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, 
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ppm): 34.5, 112.3, 115.2 (2), 127.2 (2), 130.7, 139.7, 151.3, 151.4, 157.7, 163.8. Anal. Calcd for 
C12H16N8O2S (336): C, 42.85; H, 4.79; N, 33.31. Found: C, 42.56; H, 4.98; N, 33.67. 
3.1.7. N-Carbamimidoyl-4-(5-cyano-4-oxo-3-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)-
benzenesulfonamide (8) 
A mixture of 2 (2.90 g, 0.01.mol), phenyl isothiocyanate (1.35 g, 0.01 mol) and sodium hydroxide 
(0.40 g, 0.01 mol) in ethanol (20 mL) was refluxed for 3 h. The reaction mixture was cooled, poured 
onto ice water, acidified with dilute HCl, then the solid product was filtered and crystallized from 
dioxane to give 8. Yield%: 88, m.p. = 76.4 °C, IR, cm−1: 3217, 3186, 3109 (NH, NH2), 3030 (CH 
arom.), 2982, 2861 (CH aliph.), 2193 (CN), 1374, 1199 (SO2), 1291 (C=S). 
1H-NMR (DMSO-d6, 
ppm): 6.9[s, 2H, NH2, D2O-exchangeable], 7.1–7.6[m, 9H, Ar–H], 8.3[s, 1H, CH–pyrimidine], 11.0[s, 
2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 94.9, 118.1, 121.6 (2), 122.9, 124.9 
(2), 128.4 (2), 128.6 (2), 137.7, 138.5, 139.2, 153.5, 160.6, 168.1, 187.7 (C=S). Anal. Calcd for 
C18H14N6O3S2 (426): C, 50.69; H, 3.31; N, 19.71. Found: C, 50.35; H, 3.66; N, 19.51.  
3.1.8. 4-(4-Amino-3-chloro-5-cyano-2-oxopyridin-1(2H)-yl)-N-carbamimidoylbenzenesulfonamide (9) 
A mixture of 2 (2.90 g, 0.01.mol) and chloroacetyl chloride (1.13 g, 0.01 mol) in dioxane (20 mL) 
containing 3 drops of triethylamine was refluxed for 3 h. The reaction mixture was cooled,  
poured onto ice water and the solid product was filtered and crystallized from ethanol to give 9. 
Yield%: 79, m.p. = 211.4 °C, IR, cm−1: 3408, 3276, 3204 (NH, NH2), 3100 (CH arom.), 2226 (CN), 
1736 (C=O), 1326, 1189 (SO2), 829 (C–Cl). 
1H-NMR (DMSO-d6, ppm): 4.4[s, 2H, NH2–pyridine, 
D2O-exchangeable], 7.5[s, 2H, NH2, D2O-exchangeable], 7.6–8.0[m, 4H, Ar–H], 8.6[s, 1H, CH–pyridine], 
11.3[s, 2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 91.6, 98.3, 115.9, 118.9 (2), 
127.4 (2), 136.6, 138.3, 146.2, 155.7, 166.3, 169.6. Anal. Calcd for C13H11ClN6O3S (366): C, 42.57;  
H, 3.02; N, 22.91. Found: C, 42.31; H, 3.36; N, 22.67. 
3.1.9. N-Carbamimidoyl-4-((4,6-diamino-2-thioxopyrimidin-5(2H)-ylidene)methylamino)-benzenesul-
fonamide (10) 
A mixture of 2 (2.90 g, 0.01 mol) and thiourea (0.76 g, 0.01 mol) was refluxed for 5 h in ethanol 
(20 mL) containing sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured onto ice 
water, acidified with dilute HCl, then the precipitated solid product was filtered and crystallized from 
methanol to give 10. Yield%: 90, m.p. > 350 °C, IR, cm−1: 3434, 3391, 3309 (NH, NH2), 3088 (CH 
arom.), 2976, 2819 (CH aliph.), 1384, 1151 (SO2), 1229 (C=S). 
1H-NMR (DMSO-d6, ppm): 6.4[s, 2H, 
NH2, D2O-exchangeable], 6.9[s, 4H, 2NH2–pyrimidine, D2O-exchangeable], 7.9–8.3[m, 5H, Ar–H + CH], 
10.3[s, 1H, NH, D2O-exchangeable], 11.7[s, 2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, 
ppm): 94.1, 116.5 (2), 127.7 (2), 129.3, 138.2, 143.8, 161.8, 163.6 (2), 218.9. Anal. Calcd for 
C12H14N8O2S2 (366): C, 39.33; H, 3.85; N, 30.58. Found: C, 39.62; H, 3.59; N, 30.23. 
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3.1.10. N-Carbamimidoyl-4-((3,5-dimethyl-4H-pyrazol-4-ylidene)methylamino)benzensulfonamide (11) 
Compound 5 (3.24 g, 0.01 mol) was mixed with hydrazine hydrate (0.50 g, 0.01 mol) in dioxane 
(20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated 
solid products were filtered and crystallized from methanol to give compound 11. Yield%: 90,  
m.p. = 113.9 °C, IR, cm−1: 3399, 3368, 3204 (NH, NH2), 3039 (CH arom.), 2944, 2879 (CH aliph.), 
1617 (C=N), 1308, 1179 (SO2). 
1H-NMR (DMSO-d6, ppm): 2.1[s, 6H, 2CH3], 6.6[s, 2H, NH2,  
D2O-exchangeable], 7.3–7.6[m, 5H, Ar–H + CH], 9.3[s, 1H, NH, D2O-exchangeable], 11.1[s, 2H,  
NH–imino + SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 23.0 (2), 103.1, 112.3 (2), 
127.2 (2), 130.2, 130.7, 151.3, 157.7, 167.2 (2). Anal. Calcd for C13H16N6O2S (320): C, 48.74; H, 5.03; 
N, 26.23. Found: C, 48.99; H, 5.41; N, 26.01. 
3.1.11. N-Carbamimidoyl-4-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyleneamino)benzenesulfonamide (12) 
Compound 5 (3.24 g, 0.01 mol) was mixed with methylhydrazine (0.4 g, 0.01 mol) in dioxane  
(20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated 
solid product was filtered and crystallized from methanol to give compound 12. Yield%: 76,  
m.p. = 171.8 °C, IR, cm−1: 3394, 3351, 3391 (NH, NH2), 3100 (CH arom.), 2976, 2852 (CH aliph.), 
1620 (C=N), 1309, 1178 (SO2). 
1H-NMR (DMSO-d6, ppm): 2.5[s, 6H, 2CH3], 3.4[s, 3H, NCH3], 5.6[s, 
2H, NH2, D2O-exchangeable], 6.5–7.3[m, 4H, Ar–H + CH], 7.4[s, 1H, NH–imino, D2O-exchangeable], 
8.9[s, 2H, NH + SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 13.2, 17.3, 40.0, 112.3, 
125.4 (2), 127.2 (2), 136.7, 146.8, 151.3, 157.7, 161.4, 177.8. Anal. Calcd for C14H18N6O2S (334):  
C, 50.28; H, 5.43; N, 25.13. Found: C, 50.67; H, 5.08; N, 25.36. 
3.1.12. N-Carbamimidoyl-4-((3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyleneamino)-benzenesulf-
onamide (13) 
Compound 5 (3.24 g, 0.01 mol) was mixed with phenylhydrazine (1.08 g, 0.01 mol) in dioxane  
(20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated 
solid product was filtered and crystallized from methanol to give compound 13. Yield%: 87,  
m.p. = 100.8 °C, IR, cm−1: 3386, 3320, 3220 (NH, NH2), 3099 (CH arom.), 2955, 2836 (CH aliph.), 
1598 (C=N), 1384, 1130 (SO2). 
1H-NMR (DMSO-d6, ppm): 2.5[s, 6H, 2CH3], 6.0[s, 2H, NH2,  
D2O-exchangeable], 6.5–7.7[m, 9H, Ar–H
+], 9.7[s, 1H, NH–imino, D2O-exchangeable], 9.9[s, 2H,  
NH + SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, ppm): 12.1 (CH3), 13.2 (CH3), 117.3,  
121.3 (2), 124.0 (2), 126.6, 127.3 (2), 128.6 (2), 139.0, 139.6, 147.4, 150.8, 157.6, 158.0, 172.1.  
Anal. Calcd for C19H20N6O2S (396): C, 57.56; H, 5.08; N, 21.20. Found: C, 57.36; H, 5.24; N, 21.59. 
3.1.13. N-Carbamimidoyl-4-((4,6-dimethyl-2-thioxopyrimidin-5(2H)-ylidene)methylamino) benzene-
sulfonamide (14) 
A mixture of 5 (3.24 g, 0.01 mol) and thiourea (0.76 g, 0.01 mol) was refluxed for 5 h in ethanol 
(20 mL) containing sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured onto ice 
water, acidified with dilute HCl, then the precipitated solid product was filtered and crystallized from 
methanol to give 14. Yield%: 89, m.p. > 350 °C, IR, cm−1: 3427, 3393, 3286 (NH, NH2), 3076  
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(CH arom.), 2971, 2876 (CH aliph.), 1636 (C=N), 1386, 1161 (SO2), 1246 (C=S). 
1H-NMR (DMSO-d6, 
ppm): 0.8[s, 6H, 2CH3], 6.4[s, 2H, NH2, D2O-exchangeable], 7.2–7.4[m, 5H, Ar–H + CH], 8.7[s, 1H, 
NH–imino, D2O-exchangeable], 9.4[s, 2H, NH, SO2NH, D2O-exchangeable]. 
13C-NMR (DMSO-d6, 
ppm): 19.8 (2), 86.9, 114.2 (2), 127.4, 128.6 (2), 134.1, 145.3, 162.0 (2), 173.2, 209.0 (C=S).  
Anal. Calcd for C14H16N6O2S2 (364): C, 46.14; H, 4.43; N, 23.06. Found: C, 45.89; H, 4.78; N, 23.41. 
3.1.14. (E)-4-(5-Acetyl-4-hydroxy-2-(phenylimino)pyridine-1(2H)-yl)-N-cabamimidoylbenzenesul-
fonamide (15) 
A mixture of 5 (3.24 g, 0.01 mol), phenyl isothiocyanate (1.35 g, 0.01 mol) and sodium hydroxide 
(0.4 g, 0.01 mol) in ethanol (20 mL) was refluxed for 3 h. The reaction mixture was cooled, poured 
onto ice water, acidified with dilute HCl, then the solid product was filtered and crystallized from 
dioxane to give 15. Yield%: 79, m.p. = 66.6 °C, IR, cm−1: 3436 (OH), 3208, 3186, 3121 (NH, NH2), 
3030 (CH arom.), 2982, 2861 (CH aliph.), 1706 (C=O), 1596 (C=N), 1374, 1160 (SO2). 
1H-NMR 
(DMSO-d6, ppm): 2.4[s, 3H, COCH3], 4.5[s, 1H, OH], 6.9[s, 2H, NH2, D2O-exchangeable], 7.1–7.4[m, 
9H, Ar–H], 9.4[s, 1H, NH–imino, D2O-exchangeable], 10.8[s, 1H, SO2NH, D2O-exchangeable].  
13C-NMR (DMSO-d6, ppm): 26.2, 67.1, 118.1 (2), 121.6, 122.9 (2), 124.5, 128.6 (2), 128.9, 130.8 (2), 
137.8, 142.4, 153.5, 164.9, 169.1, 171.4, 199.3. Anal. Calcd for C20H19N5O4S (425): C, 56.46; H, 4.50; 
N, 16.46. Found: C, 56.11; H, 4.89; N, 16.80. 
3.2. In-Vitro Anticancer Screening 
The human tumor cell line (MCF7) was available at the National Cancer Institute, Cairo, Egypt. The 
antitumor activity of the newly synthesized compounds was measured using the sulfo-rhodamine-B 
stain (SRB) assay by the method of Skehan et al. (1990) [35,36]. The cell lines were grown in  
RPMI 1640 medium containing 10% fetal bovine serum and 2 mM L-glutamine. Cells were plated in 
96-multiwell plates (104 cells/well), after cell inoculation, the micro titer plates were incubated at 37 °C, 
5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs to allow 
attachment of cell to the wall of the plate. After 24 h, cell line was fixed in situ with TCA (trichloro 
acetic acid). Tested compounds 3–14 were dissolved in DMSO and diluted with saline to the 
appropriate volume and maintained in RPMI 1640 medium. Different concentrations of the compounds 
under test (5, 12.5, 25, and 50 µM) were added to the cell monolayer. Triplicate wells were prepared 
for each individual dose. Monolayer cells were incubated with the compounds for 48 h at 37 °C and in 
atmosphere of 5% CO2. After 48 h, cells were fixed in situ by the gentle addition of 50 μL of cold 30% 
(w/v) TCA (final concentration, 10% TCA) and incubated for 60 min at 4 °C. The supernatant was 
discarded; the plates were washed five times with tap water and air dried. Sulforhodamine B (SRB) 
solution (50 μL) at 0.4% (w/v) in 1% acetic acid was added to each of the wells, and plates were 
incubated for 20 min at room temperature. After staining, unbounded dye was removed by four washes 
with 1% acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color intensity was 
measured in an ELISA reader (Gmbh, Viesbaden, Germany). The relation between surviving fraction 
and drug concentration was plotted to get the survival curve of each tumor cell line after the specified 
time. The concentration required for 50% inhibition of cell viability (IC50) was calculated and 
compared with the reference drug Doxorubicin and the results are given in (Table 1). 




We report in this work the synthesis of a novel series of 4-(substituted)-N-
(guanidinyl)benzenesulfonamides bearing a biologically active pyrazole, pyrimidine and pyridine 
moieties through simple and convenient routes These new derivatives were evaluated for their 
anticancer activity against human tumor breast cell line (MCF7). It was found that the most potent 
compounds in this study were the corresponding 2-cyanoacrylate 3, 3-oxobutanoate 4, pyrazole 6, 
pyridine 9 and pyrazole 13.  
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